Premium
Pulmonary metastasectomy for bone and soft tissue sarcoma in Australia: 114 patients from 1978 to 2008
Author(s) -
DEAR Rachel F,
KELLY Patrick J,
WRIGHT Gavin M,
STALLEY Paul,
MCCAUGHAN Brian C,
TATTERSALL Martin HN
Publication year - 2012
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2012.01521.x
Subject(s) - metastasectomy , medicine , chondrosarcoma , sarcoma , perioperative , proportional hazards model , soft tissue sarcoma , soft tissue , alveolar soft part sarcoma , surgery , metastasis , oncology , cancer , pathology
Aims: The aim of this study is to analyze the prognostic factors for overall and relapse‐free survival that may help select patients for pulmonary metastasectomy and inform their prognosis. Methods: From 1978 to 2008 130 patients underwent pulmonary metastasectomy for bone (osteosarcoma, chondrosarcoma and Ewing's sarcoma) and soft tissue sarcomas. Outcome measures analyzed were time to death and relapse and Cox regression models analyzed the association of prognostic factors. Results: In total 114 patients were analyzed. The 5‐year post‐metastasectomy overall survival rate was 43%. The 5‐year relapse‐free survival rate was 19%. In the multivariate analysis, an incomplete surgical resection ( P = 0.02) was associated with an increased risk of death. There was weak evidence that a diameter of the largest resected metastasis ≥ 1.8 cm ( P = 0.07) and a disease‐free interval of ≤ 18 months ( P = 0.08) were associated with an increased risk of death. Conclusion: Poor prognostic factors for overall survival after a pulmonary metastasectomy are an incomplete surgical resection, a large diameter of the biggest resected metastasis and a short disease‐free interval. The role of perioperative chemotherapy is uncertain.